Recruiting

Observational Study

Sponsor:

Henry Ford Health System

Code:

NCT05718791

Conditions

GVHD,Acute

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

blood sample

Study Details

Brief summary:

The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.

Conditions

GVHD,Acute

Study ID

NCT05718791

Start date

May 10, 2023

Status verified date

Apr, 2026

Completion date

Dec 30, 2027

Anticipated

Primary completion date

Dec 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients >18 year old admitted for allo SCT PB for malignant disease.

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Interventions

blood sample

blood sample to check CXCL9 and EASIX at day 28 post stem cell transplant

Primary outcome measure

  • predictors of acute GVHD [ Time Frame: CXCL9 combined with EASIX calculated at day 28 +/- 2 post SCT can be used as predictors of acute GVHD by day 100. ]

Central Contacts and Locations

Central contacts

shatha farhan, MD

3137133910sfarhan1@hfhs.org

Locations

Henry Ford Health System

Recruiting

Detroit, Michigan, United States, 48202

Contacts

shatha farhan

313-916-5002sfarhan1@hfhs.org

More Information

Sponsor

Henry Ford Health System

Last update posted

May 1, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Henry Ford Health System on 2026-05-01.